Cannabis Impairment Detection Device Study

An Interventional Study to Facilitate the Development of a Cannabis Impairment Detection Device in Adult Cannabis Users

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07122349

Enrollment

362

Registered

2025-08-14

Start date

2022-09-08

Completion date

2022-10-24

Last updated

2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Intoxication

Keywords

Cannabis, Marijuana, Intoxication, Impairment, Eye Test, Ocular, Drug

Brief summary

The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question\[s\] it aims to answer are: * Is the investigational device accurate and reliable at detecting cannabis impairment? * is the device safe for the collection of eye movement data from cannabis intoxicated individuals? Participants will be administered a series of Drug Recognition Expert Ocular Tests via the Gaize headset following cannabis consumption.

Interventions

DEVICECannabis Impairment Test

Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults 19, years or older, having given written informed consent to participate in the research trial and certifying that they will not drive for a period of at least 6 hours post discharge. * Having used cannabis at least one time prior * Having access to legal cannabis * Normal or corrected to normal vision using either glasses or contact lenses, or surgery.

Exclusion criteria

* Enrolled in, or participated in another clinical trial within 30 days before the study * Having a prosthetic eye * Blood pressure greater than 160/90 mmHg and heart rate greater than 100 bpm.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of device/procedure related Adverse Events/Serious Adverse Events during study intervention	Immediately after testing.	Number of participants experiencing complications related to the investigational device (headache, dizziness, nausea, etc.)

Secondary

Measure	Time frame	Description
Drug Recognition Expert Protocol Eye Test Scores	up to 90 minutes	Correlation between scores at baseline and post cannabis consumption (10 min, 30 min, 60 min, 90 min)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026